GF Fund Management Boosts Stake in Vertex Pharmaceuticals

The investment firm increased its position in the biotech company by 4.2% in the fourth quarter.

Apr. 18, 2026 at 8:57am

Got story updates? Submit your updates here. ›

An extreme close-up of gleaming metal pharmaceutical equipment and machinery, conveying the sophisticated technology and engineering behind Vertex's innovative drug development.Vertex Pharmaceuticals' advanced drug production capabilities continue to draw investor interest as the company pioneers new treatments for serious diseases.Boston Today

GF Fund Management CO. LTD. grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund now owns 65,411 shares of the pharmaceutical company's stock worth $29,655,000.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases like cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many patients. GF Fund Management's increased stake signals confidence in Vertex's future growth potential.

The details

Several other large investors have also bought and sold shares of VRTX. Brighton Jones LLC raised its holdings in Vertex Pharmaceuticals by 15.0% in the fourth quarter. NewEdge Advisors LLC raised its position by 9.0% in the second quarter. ICW Investment Advisors LLC and Diversify Advisory Services LLC also increased their stakes in the company during this period.

  • GF Fund Management disclosed the increased stake in its 4th quarter SEC filing.
  • The fund added 2,620 shares to its Vertex Pharmaceuticals position during the 4th quarter.

The players

GF Fund Management CO. LTD.

An investment management firm that grew its position in Vertex Pharmaceuticals by 4.2% in the fourth quarter.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Vertex Pharmaceuticals' innovative treatments for cystic fibrosis and other diseases continue to attract investment from major institutional funds like GF Fund Management. The company's strong pipeline and market position make it an attractive long-term play in the biotech sector.